Medication Augmentation for Persistent Aggression in ADHD with ODD

Treatment Algorithm for Persistent Aggression

The American Academy of Child and Adolescent Psychiatry recommends adding risperidone to the current regimen of stimulants and guanfacine when aggressive outbursts and fighting persist despite adequate treatment, with a dosing range of 0.5-3.5 mg/day based on response 1, 2
The American Academy of Pediatrics suggests verifying adequate stimulant dosing and timing, as stimulants have demonstrated efficacy in decreasing antisocial behaviors including fighting when ADHD drives the aggression, with a recommended dose optimization or extended coverage throughout the school day 4, 5
The American Academy of Child and Adolescent Psychiatry recommends confirming guanfacine is at therapeutic dose, with a target range of 0.05-0.12 mg/kg/day, typically 4-7 mg daily in this age group, and allowing adequate time for guanfacine effect, with treatment effects not observed until 2-4 weeks after initiation or dose adjustment 1, 3

The American Academy of Child and Adolescent Psychiatry advises monitoring closely for metabolic and neurological side effects, including weight gain, increased appetite, sedation, fatigue, drooling, extrapyramidal symptoms, and prolactin elevation 1, 2, 4, 6
The American Academy of Pediatrics recommends obtaining baseline and periodic monitoring of weight, BMI, waist circumference, fasting glucose and lipid panel, prolactin level, and movement disorder assessment 1, 2, 5, 6

The American Academy of Child and Adolescent Psychiatry suggests that if metabolic concerns are paramount, aripiprazole may be preferred over risperidone, with a dosing range of 5-15 mg daily and a lower metabolic burden than risperidone 1, 3

The American Academy of Child and Adolescent Psychiatry advises avoiding benzodiazepines for chronic behavioral management due to risk of disinhibition and behavioral side effects in children 2
The American Academy of Pediatrics recommends not adding another stimulant, as combining stimulants is not evidence-based, and clonidine is not indicated as the patient is already on guanfacine, another alpha-2 agonist 4, 5, 6

The American Academy of Child and Adolescent Psychiatry emphasizes that medication augmentation must occur within comprehensive behavioral treatment, including parent behavioral training, school-based behavioral intervention plan, cognitive behavioral therapy for anger management, and functional behavioral assessment to identify triggers for fighting 2, 3, 5